Vimarsana
Biggest News Aggregation in the World

Page 23 - Project Bioshield News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Project Bioshield. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Project Bioshield Today - Breaking & Trending Today

Soligenix to Present at the H.C. Wainwright 24th Annual Global Investment Conference - Vimarsana News

Soligenix to Present at the H.C. Wainwright 24th Annual Global Investment Conference

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma - Vimarsana News

U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

Epidemic and Infectious Disease Surveillance : Rise of the Security–Military Framework - Vimarsana News

Epidemic and Infectious Disease Surveillance : Rise of the Security–Military Framework

The COVID-19 pandemic has seen some Asian countries employ sophisticated mass-surveillance technologies—normally employed to gather intelligence for domestic security purposes—to contain the spread of infection in their populations. There has also been an intrusion of military and allied national security actors into the traditionally civilian domain of public health, in the

Source: epw.in
Soligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - Vimarsana News

Soligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

Soligenix Announces Strategic Partnership with SERB Pharmaceuticals to Supply its Novel Ricin Antigen - Vimarsana News

Soligenix Announces Strategic Partnership with SERB Pharmaceuticals to Supply its Novel Ricin Antigen

SERB Pharmaceuticals pursuing therapeutic treatment against ricin poisoning using Soligenix ricin antigenPRINCETON, N.J., July 25, 2022 /PRNewswir...